SAN DIEGO, April 8, 2019 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) announced today that it will
report first quarter financial results after the Nasdaq market
closes on Monday, April 29, 2019.
Neurocrine will then host a conference call and webcast to discuss
its financial results and provide a Company update that day at
1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Participants can access the live conference call by dialing
877-876-9173 (US) or 785-424-1667 (International) using the
conference ID: NBIX. The webcast can also be accessed on
Neurocrine's website under Investors at www.neurocrine.com. A
replay of the webcast will be available on the website
approximately one hour after the conclusion of the event and will
be archived for approximately one month.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, a San Diego based
biopharmaceutical company, is focused on developing treatments for
neurological and endocrine related disorders. The company
discovered, developed and markets
INGREZZA® (valbenazine) capsules, the
first FDA-approved treatment for adults with tardive
dyskinesia, an involuntary movement disorder. Neurocrine also
discovered and led the Phase II clinical development of
ORILISSA® (elagolix), the first FDA-approved
oral medication for the management of endometriosis with associated
moderate to severe pain in over a decade, which is marketed
by AbbVie as part of a collaboration to develop and
commercialize elagolix for women's health. Neurocrine's clinical
development programs include opicapone, an adjunctive therapy to
levodopa/DOPA decarboxylase inhibitors for Parkinson's disease
patients, elagolix for uterine fibroids (with AbbVie),
valbenazine for the treatment of Tourette syndrome, NBI-74788 for
the treatment of congenital adrenal hyperplasia (CAH), and
early-stage gene therapies for neurological disorders including
Parkinson's disease and Friedreich's ataxia, acquired through a
collaboration with Voyager Therapeutics. For more information
and the latest updates from Neurocrine Biosciences, please
visit www.neurocrine.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2019-financial-results-300826326.html
SOURCE Neurocrine Biosciences, Inc.